The Molecular Characteristics of Non-Clear Cell Renal Cell Carcinoma: What’s the Story Morning Glory?

Marchetti, Andrea; Rosellini, Matteo; Mollica, Veronica; Rizzo, Alessandro; Tassinari, Elisa; Nuvola, Giacomo; Cimadamore, Alessia; Santoni, Matteo; Fiorentino, Michelangelo; Montironi, Rodolfo; Massari, Francesco

doi:10.3390/ijms22126237

Cited by 20 publications

(7 citation statements)

References 125 publications

(141 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…RCC is the most common malignant tumor type of the urinary system. RCC may be classified by pathological subtype, among which clear cell renal cell carcinoma (ccRCC) is the most prevalent, accounting for 75–80% of RCC cases ( 22 ). Approximately 30% of patients with ccRCC develop metastatic RCC after curative nephrectomy ( 23 ) and are the high-risk population for RCC-associated death ( 24 ).…”

Section: Discussionmentioning

confidence: 99%

miR‑5590‑3p inhibits the proliferation and metastasis of renal cancer cells by targeting ROCK2 to inhibit proliferation, migration and invasion

et al. 2022

View full text Add to dashboard Cite

The present study aimed to clarify the role of microRNA (miR)-5590-3p in the progression of renal cell carcinoma (RCC) and investigate the underlying mechanisms. The expression levels of miR-5590-3p, Rho-associated protein kinase (ROCK)2 and β-catenin in RCC cells were measured by reverse transcription-quantitative PCR and western blot analysis. Following overexpression of miR-5590-3p and ROCK2 by transfection of miR-5590-3p mimics and GV367-ROCK2, respectively, changes in the proliferation, migration and invasion of RCC cells were determined through colony-formation, wound-healing and Transwell assays, respectively. The direct binding interaction between miR-5590-3p and ROCK2, initially predicted using Targetscan, was validated by a dual-luciferase reporter assay. The results indicated that miR-5590-3p was downregulated in RCC. Overexpression of miR-5590-3p led to downregulation of ROCK2 and β-catenin and inhibited the proliferation, migration and invasion of RCC cells. The dual-luciferase reporter assay confirmed the binding relationship between miR-5590-3p and ROCK2. Of note, overexpression of ROCK2 effectively reversed the regulatory effects of miR-5590-3p on RCC cells. In conclusion, miR-5590-3p inhibits the proliferation, migration and invasion of RCC cells by targeting ROCK2, which is a potential molecular biomarker and therapeutic target for RCC.

show abstract

Section: Discussionmentioning

confidence: 99%

miR‑5590‑3p inhibits the proliferation and metastasis of renal cancer cells by targeting ROCK2 to inhibit proliferation, migration and invasion

et al. 2022

View full text Add to dashboard Cite

show abstract

“…There is an emerging role for multimodal treatment strategies in patients with locally advanced, nonmetastatic RCC, including those with IVC tumor thrombus extension. While targeted therapies have shown efficacy in ccRCC, clinical responses have notably remained low in patients with nccRCC [21] , [22] , [23] . With the advent of novel immune checkpoint inhibitors, we are witnessing unparalleled rates of complete pathologic response in the primary tumors of patients undergoing nephrectomy following receipt of systemic immunotherapy, ranging from 10% to 20% [24] , [25] , [26] .…”

Section: Discussionmentioning

confidence: 99%

Characterizing Tumor Thrombus Arising from Non–Clear Cell Renal Cell Carcinoma

Esfandiary

Cheaib

Patel

et al. 2022

European Urology Open Science

View full text Add to dashboard Cite

“…The results showed promising clinical activity in the overall nonccRCC population: in particular, better overall response was detected in pRCC patients compared to chRCC, the third major RCC subtype. The clinical responses correlate with high PD-L1 expression [104,105 ▪ ]. According to these results, Pembrolizumab was introduced as a first-line treatment option for pRCC.…”

Section: Molecular Background Of Papillary Renal Cancer – Recent Deve...mentioning

confidence: 97%

Papillary renal cell carcinoma: current and controversial issues

Angori

Lobo

Moch

2022

Current Opinion in Urology

View full text Add to dashboard Cite

Purpose of reviewPapillary renal cell carcinoma (pRCC) is the second most frequent renal cancer subtype and represents 15--20% of all RCC. Classification of pRCC is changing because novel tumour entities have been discovered in the last years. In this review, we summarise recent studies relevant for the understanding of the molecular complexity and the broader differential diagnosis of pRCC. Recent findingsIt has been 25 years ago, that pRCC was morphologically subdivided into type 1 and type 2. Recently described tumour entities in the 2022 WHO classification challenged this concept and allow a new view on the molecular background in pRCC. Biphasic hyalinizing psammomatous RCC and papillary renal neoplasm with reversed polarity are emerging tumour entities derived from the new concept of molecularly defined RCC subtypes. Immune checkpoint inhibition and tyrosine kinase inhibitors have been introduced as the new backbone in the first-line treatment of advanced pRCCs. To identify novel targeted treatments for patients with pRCC it is crucial to investigate the specific molecular background of pRCC considering emerging pRCC subtypes.

show abstract

The Molecular Characteristics of Non-Clear Cell Renal Cell Carcinoma: What’s the Story Morning Glory?

Cited by 20 publications

References 125 publications

miR‑5590‑3p inhibits the proliferation and metastasis of renal cancer cells by targeting ROCK2 to inhibit proliferation, migration and invasion

miR‑5590‑3p inhibits the proliferation and metastasis of renal cancer cells by targeting ROCK2 to inhibit proliferation, migration and invasion

Characterizing Tumor Thrombus Arising from Non–Clear Cell Renal Cell Carcinoma

Papillary renal cell carcinoma: current and controversial issues

Contact Info

Product

Resources

About